Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

And just to be clear, Merck is a company I like, which, I believe, has amazing fundamentals. You don't need me to make the bull case for Merck: 9 of the last 10 articles on Seeking Alpha have a ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...

Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical giant’s CEO mentioned this in the Q4 earnings call ...

OpenAI has revealed a total rebrand with updated logos and fonts . Its update includes a fresh brand identity with a new typeface, wordmark, symbol and color palette, but there have been no ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2025 Fortune Media IP Limited ...

Courtney Breen, senior analyst of U.S. biopharmaceuticals at Bernstein, discusses Merck's slump in the market following its halt of Gardasil and HPV vaccine shipments in China. February 04, 2025 at ...

Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and ...